{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:15:49Z","timestamp":1792451749742,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108316","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:36:32Z","timestamp":1783712192000},"page":"108316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody\u2013drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"S.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-9578","authenticated-orcid":false,"given":"M.-L.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-7108","authenticated-orcid":false,"given":"G.","family":"Argil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-1047","authenticated-orcid":false,"given":"A.A.","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Z.","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-8801","authenticated-orcid":false,"given":"E.B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-0586","authenticated-orcid":false,"given":"N.","family":"Kl\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Le Bescond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6813-0395","authenticated-orcid":false,"given":"F.","family":"Lopez-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-7836","authenticated-orcid":false,"given":"G.","family":"Mountzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7575-3870","authenticated-orcid":false,"given":"A.","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"B.","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"J.","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1237-195X","authenticated-orcid":false,"given":"T.","family":"Schmelzle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Skynner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-1817","authenticated-orcid":false,"given":"E.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-8870","authenticated-orcid":false,"given":"R.A.","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmoop.2026.108316_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","article-title":"Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation","volume":"35","author":"Peters","year":"2024","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108316_bib2","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108316_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Fang","year":"2025","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108316_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108316_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108316_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108316_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.108316_bib8","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108316_bib9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108316_bib10","doi-asserted-by":"crossref","first-page":"S1566","DOI":"10.1016\/j.annonc.2025.09.031","volume":"36","author":"Dent","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108316_bib11","article-title":"LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108316_bib12","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108316_bib13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108316_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108316_bib15","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108316_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108316_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N Engl J Med"},{"issue":"3 suppl 1","key":"10.1016\/j.esmoop.2026.108316_bib18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","article-title":"1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2026.108316_bib19","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108316_bib21","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108316_bib22","author":"Metzger","year":"2024"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108316_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAI.0b013e31821c821c","article-title":"HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment","volume":"20","author":"Kunz","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"25","key":"10.1016\/j.esmoop.2026.108316_bib24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108316_bib25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108316_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2025.43.4_suppl.448","volume":"43","author":"Janjigian","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108316_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108316_bib28","article-title":"Nectin-4 positivity in genitourinary malignancies: a systematic review","volume":"8","author":"Crupi","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108316_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108316_bib30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euf.2024.04.001","article-title":"Biomarkers of response to anti-NECTIN4 antibody-drug conjugate enfortumab vedotin in urothelial cancer","volume":"10","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"20","key":"10.1016\/j.esmoop.2026.108316_bib31","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108316_bib32","doi-asserted-by":"crossref","first-page":"S1494","DOI":"10.1016\/j.annonc.2025.08.3701","article-title":"3087P NECTIN4 Amplification as a predictive biomarker of response to enfortumab vedotin plus pembrolizumab in first-line metastatic urothelial carcinoma: a multicenter cohort study","volume":"36","author":"Kl\u00fcmper","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108316_bib33","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2025.43.16_suppl.4575","article-title":"Impact of histological subtypes in patients receiving first-line treatment with enfortumab vedotin\/pembrolizumab in advanced metastatic urothelial cancer","volume":"43","author":"Abdelnaser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108316_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108316_bib36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 10","key":"10.1016\/j.esmoop.2026.108316_bib38","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108316_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41571-025-01110-1","article-title":"The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology","volume":"23","author":"Johnson","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108316_bib40","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108316_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108316_bib42","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/JCO.2025.43.16_suppl.4567","article-title":"Phase 1\/2 Duravelo-1 study: Preliminary results of nectin-4\u2013targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"43","author":"Giannatempo","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108316_bib44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-22-0804","article-title":"Use of payload binding selectivity enhancers to improve therapeutic index of maytansinoid-antibody-drug conjugates","volume":"22","author":"Nguyen","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108316_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108316_bib46","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108316_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108316_bib48","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108316_bib49","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/d41573-025-00096-w","article-title":"The landscape for radioligand therapies in oncology","volume":"24","author":"To","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108316_bib50","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","article-title":"Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial","volume":"31","author":"Pistilli","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108316_bib51","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108316_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61957-9","article-title":"HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer","volume":"14","author":"Kapil","year":"2024","journal-title":"Sci Rep"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:34:08Z","timestamp":1787848448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022581"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108316","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody\u2013drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108316"}}